[go: up one dir, main page]

ATE426397T1 - Copolymer-zusammensetzungen zur oralen verabreichung - Google Patents

Copolymer-zusammensetzungen zur oralen verabreichung

Info

Publication number
ATE426397T1
ATE426397T1 AT99904594T AT99904594T ATE426397T1 AT E426397 T1 ATE426397 T1 AT E426397T1 AT 99904594 T AT99904594 T AT 99904594T AT 99904594 T AT99904594 T AT 99904594T AT E426397 T1 ATE426397 T1 AT E426397T1
Authority
AT
Austria
Prior art keywords
oral administration
copolymer compositions
compositions
poly
oral delivery
Prior art date
Application number
AT99904594T
Other languages
English (en)
Inventor
Alexander V Kabanov
Valery Y Alakov
Elena V Batrakova
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ATE426397T1 publication Critical patent/ATE426397T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
AT99904594T 1998-02-06 1999-02-05 Copolymer-zusammensetzungen zur oralen verabreichung ATE426397T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/019,648 US6277410B1 (en) 1992-10-08 1998-02-06 Copolymer compositions for oral delivery

Publications (1)

Publication Number Publication Date
ATE426397T1 true ATE426397T1 (de) 2009-04-15

Family

ID=21794304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99904594T ATE426397T1 (de) 1998-02-06 1999-02-05 Copolymer-zusammensetzungen zur oralen verabreichung

Country Status (8)

Country Link
US (2) US6277410B1 (de)
EP (1) EP1053010B1 (de)
JP (1) JP4685237B2 (de)
AT (1) ATE426397T1 (de)
AU (1) AU2496199A (de)
CA (1) CA2319057C (de)
DE (1) DE69940635D1 (de)
WO (1) WO1999039731A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
EP1563850A3 (de) * 2000-02-23 2008-02-20 Pfizer Products Inc. Verfahren zur Erhöhung der Bioverfügbarkeit und dem Eindringen in Gefässe von Azithromycin
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
JP2004509838A (ja) * 2000-04-28 2004-04-02 スプラテック　ファーマ　インコーポレイティド 樹状細胞の活性化誘導のための組成物および方法
ATE401095T1 (de) * 2000-05-26 2008-08-15 Frohwitter Bernhard Mittel zum erhalten und/oder korrigieren der blutglukosekonzentration
AU2002254342A1 (en) 2001-03-23 2002-10-08 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0131112D0 (en) * 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
CN100438861C (zh) * 2002-07-29 2008-12-03 变换药品公司 含水2,6-二异丙基苯酚药物组合物
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
HUE034378T2 (en) 2002-10-16 2018-02-28 Purdue Pharma Lp Cell-associated CA 125 / O722P binding antibodies and methods of use
US7422875B2 (en) 2004-07-20 2008-09-09 Board Of Regents Of The University Of Nebraska Compositions and methods for increasing protein production
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
BRPI0706383A2 (pt) * 2006-01-10 2011-03-22 Innovaform Technologies Llc composição pesticida, concentrado, dispersão, e, métodos para preparar uma composição e para controlar pestes
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
RU2409363C9 (ru) * 2009-09-18 2013-12-10 Всеволод Иванович Киселев Фармацевтические композиции для пероральной доставки дииндолилметана (dim) и способы применения этих композиций
US8946301B2 (en) 2011-11-29 2015-02-03 Als Therapy Development Institute Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis
US8912215B2 (en) * 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4106474A (en) 1977-03-17 1978-08-15 Modine Manufacturing Company Heat conserving space heater
US4865835A (en) 1982-06-02 1989-09-12 Begent Richard H J Diagnosis and treatment of tumors
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
ES8601706A1 (es) * 1983-05-16 1985-11-16 Merck & Co Inc Una composicion farmaceutica
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4485457A (en) 1983-05-31 1984-11-27 Cbs Inc. Memory system including RAM and page switchable ROM
US4772466A (en) 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
JPS61103836A (ja) 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
WO1986007539A1 (en) * 1985-06-18 1986-12-31 Emory University Biologically-active copolymers
US5234683A (en) 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5494660A (en) 1985-06-18 1996-02-27 Emory University Method for inhibiting microbial binding to surfaces
US5183687A (en) 1985-06-18 1993-02-02 Emory University Method of treating poultry for coccidiosis
US5114708A (en) 1985-06-18 1992-05-19 Emory University Method for stimulating growth in animals
US5466445A (en) 1985-06-18 1995-11-14 Emory University Methods for reducing salmonella in chickens
AU6073386A (en) 1985-07-30 1987-02-05 International Minerals & Chemical Corporation Stabilization of growth promoting hormones
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US4873083A (en) 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US5017370A (en) 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US4801452A (en) 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5064643A (en) 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4997644A (en) 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US5039520A (en) 1986-05-15 1991-08-13 Emory University Plasma extender
US5047236A (en) 1986-05-15 1991-09-10 Emory University Method of treating stroke
US5250294A (en) 1986-05-15 1993-10-05 Emory University Improved perfusion medium for transplantation of organs
US5182106A (en) 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
US5041288A (en) 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5071649A (en) 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5080894A (en) 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US5089260A (en) 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US5240701A (en) 1986-05-15 1993-08-31 Emory University Method of performing angioplasty procedures
US4897263A (en) 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5032394A (en) 1986-05-15 1991-07-16 Emory University Method of treating burns
US5152979A (en) 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5240702A (en) 1986-05-15 1993-08-31 Emory University Method of treating stroke
US4837014A (en) 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US4937070A (en) 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5078995A (en) 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US4882168A (en) 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH01501064A (ja) * 1986-09-22 1989-04-13 エモリ　ユニバーシティ ワクチンとその製法
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US5567859A (en) * 1991-03-19 1996-10-22 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
EP0305470B1 (de) * 1987-02-20 1992-11-11 Emory University Antiinfektiöse verbindungen und verfahren zur verwendung
ATE113724T1 (de) 1987-07-27 1994-11-15 Commw Scient Ind Res Org Rezeptormembranen.
US4853228A (en) 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
CA2081340A1 (en) * 1990-04-26 1991-10-27 R. Martin Emanuele Composition and method for topical treatment of damaged or diseased tissue
NZ238731A (en) * 1990-06-27 1996-02-27 Univ Emory Vaccine adjuvant compositions comprising ethyleneoxy-propyleneoxy-ethyleneoxy block copolymer or a non-toxic lipopolysaccharide
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JP2647556B2 (ja) * 1991-03-19 1997-08-27 サイトアーレクス・コーポレーシヨン 改良された生物学的活性を有するポリオキシプロピレン／ポリオキシエチレン共重合体類
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
EP0643620B1 (de) 1991-10-04 1999-07-21 Gs Development Ab Teilchen, methode zur herstellung der teilchen und deren verwendung
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
US5470568A (en) 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6153193A (en) 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
JPH08506319A (ja) 1992-10-08 1996-07-09 ヴァレリ ユ． アラホフ ミセル中に組み込まれた抗−新生物性組成物
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
JP3946246B2 (ja) 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
IL106578A (en) 1993-08-03 2000-08-13 Yissum Res Dev Co Pharmaceutical compositions for drug targeting
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US5401296A (en) 1994-06-28 1995-03-28 Martenson; Irvin Precious metal extraction process
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
JP4117922B2 (ja) * 1996-03-28 2008-07-16 武田薬品工業株式会社 徐放性製剤およびその製造法

Also Published As

Publication number Publication date
AU2496199A (en) 1999-08-23
CA2319057A1 (en) 1999-08-12
EP1053010B1 (de) 2009-03-25
EP1053010A1 (de) 2000-11-22
JP4685237B2 (ja) 2011-05-18
US6387406B1 (en) 2002-05-14
EP1053010A4 (de) 2002-08-21
DE69940635D1 (de) 2009-05-07
CA2319057C (en) 2010-05-04
WO1999039731A1 (en) 1999-08-12
US6277410B1 (en) 2001-08-21
JP2002502825A (ja) 2002-01-29

Similar Documents

Publication Publication Date Title
DE69940635D1 (de) Copolymer-zusammensetzungen zur oralen verabreichung
TR200100054T2 (tr) Paroksetin metansülfonat
MXPA03009772A (es) Metodos y composiciones para tratar lesiones orales y del esofago.
BR9916857A (pt) 4 heteroaril diarilaminas
DK1117440T3 (da) Farmaceutiske sammensætninger indeholdende paclitaxel
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
TR200002299T2 (tr) Epotilon kompozisyonları.
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
MXPA03010085A (es) Composiciones y su uso en la hiperplasia.
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DE69905170T2 (de) Thiazolopyrimidinderivate
BRPI0407583A (pt) solução oftálmica lìmpida e estável
GEP20074024B (en) Polyalkylene glycol comprising a radical for conjugation of biologically active compound
ATE504308T1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
DE60216305D1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
BR0008228A (pt) Composições de n-benzoil estaurosporinaespontaneamente dispersìveis
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
BR0213379A (pt) Formulação resistente a derramamento de mascaramento de gosto
BR9712498A (pt) Ingredientes de detergente de aminaquaternizados, alcoxilados
YU13301A (sh) Muskarinski agonisti i antagonisti
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties